-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
You May Also Like
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Healthy Hearts and Healthy Wallets: Why one HealthTech Startup is a Must-Invest
6 Companies That Could Fix Domestic Battery Supply Problem Using Little To No Emissions In The Mining of Essential Minerals
-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
-
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to WebMD. It’s said to be the leading cause of severe, permanent vision loss in people older than 60. When the macula — the small central portion of the retina — wears down, the light-sensing nerve tissue at the back of the eye begins to deteriorate. While it doesn’t always cause complete blindness, severe vision problems such as loss of central vision may occur. As the condition worsens,…
